Pentoxifylline may be Potentially Harmful in the Treatment of Peripartum Cardiomyopathy 

Olaf Forster*
Received Date: February 08, 2022 Accepted Date: March 08, 2022 Published Date: March 10, 2022

doi: 10.17303/jcvm.2022.8.102

Citation: Olaf Forster (2022) Pentoxifylline may be Potentially Harmful in the Treatment of Peripartum Cardiomyopathy. J Cardio Vasc Med 1: 1-10.

ABSTRACT FULL TEXT REFERENCES TABLES & FIGURES

 References

  1. Sliwa K (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12(8): 767-78.
  2. Patten IS (2012) Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485(7398): 333-8.
  3. Hilfiker-Kleiner D (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell, 128: 589-600.
  4. Arany Z, U Elkayam (2016) Peripartum Cardiomyopathy. Circulation 133: 1397-409.
  5. van Spaendonck-Zwarts KY (2010) Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 121: 2169-75.
  6. Bhattacharyya A (2012) Peripartum cardiomyopathy: a review. Tex Heart Inst J 39: 8-16.
  7. Morales A (2010) Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 121: 2176-82.
  8. Burton GJ, E Jauniaux (2011) Oxidative stress. Best Pract Res Clin Obstet Gynaecol 25: 287-99.
  9. Forster O (2008) Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 10: 861-8.
  10. Ntusi NB, BM Mayosi (2009) Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol 131: 168-79.
  11. Koczo A (2021) Proinflammatory TH17 cytokine activation, disease severity and outcomes in peripartum cardiomyopathy. Int J Cardiol 339: 93-8.
  12. Sliwa K (2006) Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 27: 441-6.
  13. Sliwa K (1998) Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351: 1091-3.
  14. Skudicky D (2001) Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 103: 1083-8.
  15. Champion S (2014) Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovasc Ther 32: 159-62.
  16. Showell MG (2017) Antioxidants for female subfertility. Cochrane Database Syst Rev 7: Cd007807.
  17. Desplantie O (2015) The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies. Can J Cardiol 31: 1421-6.
  18. Sliwa K (2002) The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4: 305-9.
  19. Sliwa K (2002) Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol 90: 1118-22.
  20. Siwik DA, DL Chang, WS Colucci (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259-65.
  21. Dezube BJ (1995) High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 171: 1628-32.
  22. Chartier M, V Falanga (2009) Healing of ulcers due to cryofibrinogenemia with colchicine and high-dose pentoxifylline. Am J Clin Dermatol 10: 39-42.
  23. Jull AB (2012) Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev 12: Cd001733.
  24. Falanga V (1999) Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial. Wound Repair Regen 7: 208-13.
  25. Wenisch C (1998) Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria. Am J Trop Med Hyg 58: 343-7.
  26. Sahn DJ (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58: 1072-83.
  27. Forster O (2006) Untreated human immunodeficiency virus (HIV) - infection does not influence outcome in peripartum cardiomyopathy patients. in ESC Conference. Barcelona.
  28. Seirafianpour F (2020) Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther 33: e13733.
  29. Wen WX (2017) Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Adv Ther 34: 1245-69.
  30. Aifantis KE (2019) Relating the blood-thinning effect of pentoxifylline to the reduction in the elastic modulus of human red blood cells: an in vivo study. Biomater Sci 7: 2545-551.
  31. Maiti R (2007) Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 47: 118-24.
  32. Müller R, F Lebrach (1980) Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica 2: 372-9.
  33. Belloc F (1995) Effect of pentoxifylline on apoptosis of cultured cells. J Cardiovasc Pharmacol 25: S71-4.
  34. Suresh R (2002) Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death. J Immunol 169: 4262-72.
  35. Rauchhaus M (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 102: 3060-7.
  36. Gupta SK (2013) Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. PLoS One 8: e60852.
  37. Dezube BJ (1993) Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immune Defic Syndr (1988) 6: 787-94.
  38. Sliwa K (2004) Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation 109: 750-5.
  39. Batchelder K, BM Mayosi (2005) Pentoxifylline for heart failure: a systematic review. S Afr Med J 95: 171-5.
  40. Harris E, SM Schulzke, SK Patole (2010) Pentoxifylline in preterm neonates: a systematic review. Paediatr Drugs, 12: 301-11.
  41. Champion S (2014) Pentoxifylline in heart failure: a meta-analysis of clinical trials. Cardiovasc Ther 32: 159-62.
  42. Isezuo SA, SA Abubakar (2007) Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis, 2007. 17: 228-33.
  43. Karaye KM, MY Henein (2013) Peripartum cardiomyopathy: a review article. Int J Cardiol 164: 33-8.
  44. Sliwa K (2020) Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J 41: 3787-97.
  45. Fett JD (2020) Promoting awareness of peripartum cardiomyopathy (PPCM). Int J Cardiol 305: 113-114.
  46. Thompson JA (1993) Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Semin Oncol 20: 46-51.
  47. Han SJ (2015) Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study. Diabetol Metab Syndr 7: 64.
  48. Tian ML (2015) Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol 47: 815-22.
  49. Ravera M (2007) Emerging therapeutic strategies in diabetic nephropathy. J Nephrol 20: S23-32.
  50. Navarro J (1996) Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kappa B activation. Aids 10: 469-75.
  51. Smith JA (2007) Pentoxifylline suppresses transduction by HIV-1-based vectors. Intervirology 50: 377-86.
  52. Dezube BJ, MM Lederman (1995) Pentoxifylline for the treatment of HIV infection and its complications. J Cardiovasc Pharmacol 25: S139-42.
  53. Green LA (2012) Pentoxifylline reduces tumor necrosis factor-alpha and HIV-induced vascular endothelial activation. AIDS Res Hum Retroviruses 28: 1207-15.
  54. Gupta SK (2016) A pilot trial of pentoxifylline on endothelial function and inflammation in HIV-infected patients initiating antiretroviral therapy. AIDS 30: 2139-42.
  55. Balog DL, ME Epstein, MI Amodio-Groton (1998) HIV wasting syndrome: treatment update. Ann Pharmacother 32: 446-58.
  56. Dezube BJ (1994) Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 18: 285-7.